The use of older studies in meta-analyses of medical interventions: A survey

Open Medicine

Volumn 3, Issue 2, 2009, Pages 32-38

  Patsopoulos, Nikolaos A ^a   Ioannidis, John P A ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67650218802     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ioannidis JPA. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294(2):218-228.
2. Poynard T, Munteanu M, Ratziu V, Benhamou Y, Di Martino V, Taieb J, et al. Truth survival in clinical research: an evidence-based requiem? Ann Intern Med. 2002;136(12):888-895.
3. Hall JC, Platell C. Half-life of truth in surgical literature. Lancet. 1997;350(9093):1752.
4. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials. 2006;1(1):e9.
5. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply"? Lancet. 2005;365(9453):82-93.
6. Ioannidis JPA. Indirect comparisons: the mesh and mess of clinical trials. Lancet. 2006;368(9546):1470-1472.
7. Bero L, Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA. 1995;274(24):1935-1938.
8. Clarke M, Langhorne P. Revisiting the Cochrane Collaboration. Meeting the challenge of Archie Cochrane - and facing up to some new ones. BMJ. 2001;323(7317):821.
9. Grimshaw J. So what has the Cochrane Collaboration ever done for us? A report card on the first 10 years. CMAJ. 2004;171(7):747-749.
10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
11. Muir Gray JA. Evidence-based healthcare: how to make health policy and management decisions. London: Churchill Livingstone: 1997.
12. Djulbegovic B, Loughran TP, Hornung CA, Kloecker G, Efthimiadis EN, Hadley TJ, et al. The quality of medical evidence in hematology-oncology. Am J Med. 1999;106(2):198-205.
13. Mallett S, Clarke M. The typical Cochrane review. How many trials? How many participants. Int J Technol Assess Health Care. 2002;18(4):820-823.
14. Ioannidis J, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proc Natl Acad Sci U S A. 2001;98(3):831-836.
15. Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, et al. EU-PSI project. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol. 2004;57(11):1124-1130.
16. Gehr BT, Weiss C, Porzsolt F. The fading of reported effectiveness. A meta-analysis of randomised controlled trials. BMC Med Res Methodol. 2006;6:25-26.
17. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279(4):281-286.
18. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ. 1997;315(7109):640-645.
19. Hopewell S, Clarke MJ, Stewart L, Tierney J. Time to publication for results of clinical trials. Cochrane Database of Systematic Reviews. . 2007;(Issue 2)
20. Ioannidis JP, Cappelleri JC, Sacks HS, Lau J. The relationship between study design, results, and reporting of randomized clinical trials of HIV infection. Control Clin Trials. 1997;18(5):431-444.
21. Ioannidis JP, Cappelleri JC, Lau J. Issues in comparisons between meta-analyses and large trials. JAMA. 1998;279(14):1089-1093.
22. Schulz KF. Subverting randomization in controlled trials. JAMA. 1995;274(18):1456-1458.
23. Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews. . 2003;(Issue 4)
24. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. CONSORT GROUP (Consolidated Standards of Reporting Trials). The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med. 2001;134(8):663-694.
25. Ioannidis JPA, Evans SJW, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-788.
26. Chan A, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet. 2005;365(9465):1159-1162.
27. Chan A, Krleza-Jerić K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ. 2004;171(7):735-740.
28. Chan A, Hróbjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291(20):2457-2465.
29. Chan A, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ. 2005;330(7494):753.
30. Mallett S, Clarke M. How many Cochrane reviews are needed to cover existing evidence on the effects of health care interventions. ACP J Club. 2003;139(1):A11.
31. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124.
32. Djulbegovic B, Hozo I. When should potentially false research findings be considered acceptable? PLoS Med. 2007;4(2):e26.
33. Hauben M, Reich L, Van Puijenbroek EP, Gerrits CM, Patadia VK. Data mining in pharmacovigilance: lessons from phantom ships. Eur J Clin Pharmacol. 2006;62(11):967-970.